# Klaria Pharma Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/klariapharmaholding). ## Overview Klaria Pharma Holding AB is a Swedish pharmaceutical company built around its patented Alginate Film drug-delivery platform, which places well-known active substances in a rapidly dissolving oral film that attaches to the mucosa. The group develops product candidates and combination products for therapeutic areas such as migraine, opioid overdose, anaphylactic shock, cancer-related pain, and other acute conditions, with operations centered in Sweden through its subsidiary structure. ## Products & services • Alginate Film drug-delivery platform • Sumatriptan Alginate Film • Naloxone Alginate Film • Epinephrine Alginate Film • Ketamine Alginate Film • Cannabinoids Alginate Film - **Drug-delivery platform** (0%) — Patented oral mucosal film technology used to deliver active pharmaceutical ingredients. - **Migraine products** (25%) — Sumatriptan-based film formulations developed for migraine treatment. - **Opioid overdose products** (20%) — Naloxone film formulations intended for emergency overdose reversal use. - **Anaphylaxis products** (20%) — Epinephrine film formulations designed for rapid treatment of severe allergic reactions. - **Pain and CNS products** (35%) — Ketamine and cannabinoid-based film projects for pain and related indications. - Alginate Film drug-delivery platform - Sumatriptan Alginate Film - Naloxone Alginate Film - Epinephrine Alginate Film - Ketamine Alginate Film - Cannabinoids Alginate Film ## Customers Klaria’s customers are primarily pharmaceutical partners, licensees, distributors, and other commercial counterparties that can develop, register, manufacture, or market film-based drug products. The end-use markets are patients and healthcare systems in acute-care and specialty therapeutic areas, but the company’s direct commercial counterparties are typically industry partners rather than retail consumers. Its business model depends on counterparties that value differentiated delivery, patent protection, and the ability to pair established active ingredients with a novel dosage form. - **Pharmaceutical partners** (primary) — Companies that collaborate on development, licensing, or commercialization of film-based drug candidates. - **Distributors and commercial partners** (primary) — Organizations that help bring approved products to market and expand geographic reach. - **Healthcare systems and providers** (secondary) — Hospitals, clinics, and emergency-care settings that would use rapid-acting therapies if approved and launched. - **Patients in acute indications** (secondary) — End users for migraine, opioid overdose, anaphylaxis, and pain products once commercialized. - **Research and development collaborators** (secondary) — Counterparties involved in clinical, regulatory, and formulation work around specific product candidates. - Pharmaceutical partners seeking a differentiated delivery platform - Licensees commercializing specific film-based drug combinations - Distributors and channel partners for market access - Healthcare markets needing rapid-acting acute therapies - Patients in migraine, overdose, allergy, and pain indications ## Geography Klaria is headquartered in Sweden and listed on Nasdaq First North Growth Market in Stockholm. Its patent portfolio and product-development efforts are described for Sweden, the EU/rest of the world, and the United States, reflecting a business designed for international pharmaceutical markets rather than a single domestic market. - **Sweden** (100%) — Head office and primary group operations are in Sweden. - Headquartered in Sweden with group operations centered there - Listed on Nasdaq First North Growth Market in Stockholm - Patent coverage spans Sweden, the EU/rest of world, and the US - Commercial opportunity is international because drug approvals are market-specific - Regulatory exposure differs by region due to FDA, EMA, and local authorities ## Strategy Klaria’s strategy is to protect and extend its Alginate Film platform through a patent portfolio and project-specific patent filings around each product combination. The company’s commercial logic is to pair its delivery technology with well-proven active substances in indications where rapid onset and differentiated administration can matter, then advance those programs through regulatory and partnership pathways. - **Expand and defend intellectual property** (medium-term) — Patent protection is central to preserving the platform's commercial value and partner appeal. - **Advance product candidates in high-need indications** (medium-term) — The company’s value depends on converting the platform into approved, marketable products. - **Build partnerships for development and commercialization** (short-term) — External partners are important for funding, market access, and execution across regions. - Defend the Alginate Film platform with broad patent protection - Add product-specific patents around each drug combination - Advance rapid-acting formulations in acute-care indications - Use partnerships to reach development, regulatory, and commercial scale - Target established active ingredients to reduce scientific uncertainty ## Risks Klaria faces the typical risks of a development-stage pharmaceutical company: regulatory approval uncertainty, clinical and manufacturing risk, and the possibility that product candidates do not reach market. Its platform also depends on patent strength and partner execution, so intellectual-property disputes, weak market uptake, or failed collaborations could materially limit commercialization. - **Regulatory approval risk** [critical] — Products require clinical evidence and approvals from authorities such as the FDA and EMA before sales can begin. - **Clinical development and manufacturing risk** [high] — The company must prove safety, efficacy, and manufacturability for each candidate and market. - **Intellectual property risk** [high] — Patent coverage may be incomplete, challenged, or insufficient to block competitors. - **Partner and distribution risk** [high] — Growth depends on agreements with distributors and other commercial counterparties. - **Competition risk** [medium] — Other companies may develop equivalent or better products for the same indications. - Regulatory approval is uncertain and market-specific - Clinical and manufacturing outcomes may not meet requirements - Patent protection may be incomplete or challenged - Commercial success depends on partners and distribution channels - Competition from alternative therapies can reduce adoption ## Accounting Klaria’s reporting is shaped by development-stage accounting, where revenue can be episodic and tied to milestone or performance-based contracts rather than recurring product sales. Investors should watch revenue recognition under IFRS 15, impairment testing of intangible assets, and the treatment of loss carryforwards and equity, because these areas can materially affect reported results and balance-sheet strength. - **IFRS 15 revenue recognition** — Affects timing and comparability of reported sales - **Impairment of intangible assets** — Can create material non-cash charges - **Deferred tax assets and loss carryforwards** — Affects tax asset recognition and equity - **Equity and capital structure** — Dilution and balance-sheet resilience - Revenue may depend on milestone payments and contract performance - IFRS 15 timing can create lumpy quarterly revenue recognition - Intangible assets require impairment testing when project value changes - Loss carryforwards may not be recognized as deferred tax assets - Equity and going-concern sensitivity matter for a development company --- *Last updated: 2026-08-11T04:04:53.811153+00:00*